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We read with interest the review by Lakhan and Kirchgessner, proposing that high fructose intake promotes
obesity, metabolic syndrome, diabetes, and cognitive decline. Their focus on the role of fructose seems premature
due to confounding from energy and the heavy reliance on low quality evidence from animal models. There is a
lack of high quality evidence directly assessing the role of fructose in cognitive decline. Although one cannot
exclude the possibility of a link, it remains an unconfirmed hypothesis.
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Dear Editor,
We read with interest the review by Lakhan and
Kirchgessner [1], proposing that high fructose intake
promotes obesity and its downstrean complications in-
cluding metabolic syndrome, diabetes, and cognitive de-
cline. We feel this focus on the role of fructose is
premature, as the authors did not take into consider-
ation important confounding from energy and relied
heavily on weak evidence from animal models.
Any discussion of the role of fructose in obesity and
its metabolic complications must take into consideration
energy intake and balance. We have published several
systematic reviews and meta-analyses of controlled feed-
ing trials in humans of the effect of fructose on cardio-
metabolic risk factors, demonstrating that excess calories
may be the dominant factor in mediating the effects at-
tributed to fructose. We have found that when dietary
fructose is consumed in isocaloric substitution for other
carbohydrate sources (that is, where the fructose arm is
matched for energy to the carbohydrate comparator),
there are no deleterious effects with advantages seen for
glycemic control and blood pressure [2-8]. An overall
lack of harm is true even where fructose provides excess* Correspondence: john.sievenpiper@utoronto.ca
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dyate comparator is matched for the excess calories.
Fructose, however, does show adverse signals for fasting
lipids in some high dose subgroup analyses [8-10] and
for most endpoints when it provides excess calories in
imbalanced hypercaloric comparisons, in which fructose
supplements control diets with excess calories compared
to the same diets alone without the excess calories [2-7].
In the absence of consistent adverse effects in isocaloric
comparisons, the consistent adverse effects seen in
hypercaloric comparisons suggests that excess calories
are the culprit. This view is supported by other high
quality systematic reviews and meta-analyses of the ef-
fect of other fructose-containing sugars [11,12]. It is also
supported by the secondary sources the authors them-
selves cited. Energy balance, therefore, remains an im-
portant confounder in assessing the role of fructose in
obesity and its metabolic complications including cogni-
tive decline.
One must be careful in placing too much weight on
the biological plausibility provided by animal models in
the fructose debate. The ability to translate these models
to human physiology is limited. The majority of animal
studies feed fructose at levels (typically ~60% of total en-
ergy) many fold higher than population levels of intake
[13]. De novo lipogenesis, the main pathway through
which fructose is thought to have its deleterious effects,
also appears to be very different in animals. De novo
lipogenesis from fructose accounts for 60-70% of fatty
acids in rodents, while its contribution is quantitativelyral Ltd. This is an Open Access article distributed under the terms of the Creative
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http://www.nutritionj.com/content/13/1/27insignificant [13]. Two carefully conducted reviews of
isotopic tracer studies showed that glucose (~50%), lac-
tate (~25%), and glycogenesis (>15%) synthesis remain
the major pathways of hepatic fructose disposal in
humans, while de novo lipogenesis contributes <1% of
fatty acids [14,15]. Although fructose, more than other
sources of carbohydrate, may stimulate de novo lipogen-
esis, its ability to do so in a meaningful way may only be
seen in hypercaloric comparisons, in which fructose sup-
plements diets with excess calories at extreme doses.
Overall, we feel that the conclusions of this review
should be viewed with the appropriate caution. Where we
do have higher quality evidence of the effect of fructose
on cardiometabolic risk factors associated with cognitive
decline, there is significant evidence of confounding from
energy. There is otherwise a lack of high quality evidence
directly assessing the role of fructose in cognitive decline.
Although one cannot exclude the possibility of a link, it
remains an unconfirmed hypothesis.
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